Literature DB >> 8692535

p53 and MDM2 expression in oral squamous cell carcinoma.

T Matsumura1, Y Yoshihama, T Kimura, S Shintani, R E Alcalde.   

Abstract

The p53 tumor suppressor gene is the most commonly mutated gene in human cancer and is a frequent abnormality in oral squamous cell carcinoma and its precancerous lesions. MDM2 (murine double minute-2), a new proto-oncogene, may be associated with p53 gene products and may negatively affect the transcriptional activating function of p53. The purpose of this study was to investigate the incidence of MDM2 and its relationship to the expression of p53 in oral squamous cell carcinoma and precancerous lesions. Overexpression of p53 and MDM2 proteins was detected in 52 and 40% of oral squamous cell carcinomas, respectively. p53 gene mutation, absent in normal oral epithelium was observed in 31% of the carcinoma cases. Our finding suggested that MDM2 protein may be an alternative mechanism causing p53 protein dysfunction in oral squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692535     DOI: 10.1159/000227578

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

2.  Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma.

Authors:  Marcela K Hassumi-Fukasawa; Fabiana A Miranda-Camargo; Márcia C M Guimarães; Renata T Simões; Eduardo A Donadi; Christiane P Soares; Edson G Soares
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-02-05       Impact factor: 2.503

3.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

Authors:  S N Jones; A R Hancock; H Vogel; L A Donehower; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

Authors:  Michael I Carr; Stephen N Jones
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

5.  Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.

Authors:  Sarah De Clercq; Agnieszka Gembarska; Geertrui Denecker; Marion Maetens; Michael Naessens; Katharina Haigh; Jody J Haigh; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2010-09-20       Impact factor: 4.272

6.  MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network.

Authors:  Rana Elkholi; Ioana Abraham-Enachescu; Andrew P Trotta; Camila Rubio-Patiño; Jarvier N Mohammed; Mark P A Luna-Vargas; Jesse D Gelles; Joshua R Kaminetsky; Madhavika N Serasinghe; Cindy Zou; Sumaira Ali; Gavin P McStay; Cathie M Pfleger; Jerry Edward Chipuk
Journal:  Mol Cell       Date:  2019-03-14       Impact factor: 17.970

7.  High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.

Authors:  Yasmine A Valentin-Vega; Juan A Barboza; Gilda P Chau; Adel K El-Naggar; Guillermina Lozano
Journal:  Hum Pathol       Date:  2007-07-24       Impact factor: 3.466

8.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.

Authors:  I Ganly; D S Soutar; R Brown; S B Kaye
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.